文献速递头颈外科

血管升压药对头颈癌患者游离皮瓣结局的影响

The Influence of Vasopressors on Free Flap Outcomes in Head and Neck Cancer Patients.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-08-05

这项回顾性多中心队列研究利用TriNetX网络2013年1月至2023年1月数据,比较手术当日使用与未使用血管升压药的头颈癌游离皮瓣重建患者结局。倾向评分匹配后分析7446例,两组皮瓣失败相关结局无统计学差异,作者认为临床需要时手术当日使用血管升压药可能安全。

要点

  • 倾向评分匹配后每组3723例,两组二次游离皮瓣、血管修复及其他皮瓣翻修手术率无统计学差异。
  • 骨皮瓣亚组中血管升压药组血管修复率低于非血管升压药组(6.1% vs 9.0%,P=.003)。
  • 血管升压药组肺炎、尿路感染和深静脉血栓发生率显著低于非血管升压药组。

核心结论

  • 使用血管升压药与游离皮瓣并发症无显著关联,结果提示临床需要时手术当日使用血管升压药可能安全。

研究设计与样本

  • 回顾性队列研究,纳入2013年1月至2023年1月TriNetX研究网络中80个医疗机构的头颈癌游离皮瓣重建患者。
  • 将手术当日接受与未接受血管升压药的患者分组,经倾向评分匹配后共分析7446例,每组3723例。

主要发现

  • 血管升压药组(3723例,平均年龄62.9岁[SD 11.4],男性2511例[67.4%])与非血管升压药组(3723例,平均年龄63.0岁[SD 11.2],男性2479例[66.6%])的游离皮瓣结局无统计学差异。
  • 二次游离皮瓣:血管升压药组166例(4.5%)vs 非血管升压药组155例(4.2%),P=.04;血管修复:314例(8.4%)vs 319例(8.6%),P=.06;其他皮瓣翻修手术:416例(11.2%)vs 449例(12.1%),P=.02。
  • 骨皮瓣血管修复率血管升压药组47例(6.1%)vs 非血管升压药组69例(9.0%),P=.003。
  • 次要结局中,肺炎173例(4.6%)vs 231例(6.2%),P=.0002;尿路感染34例(1.0%)vs 59例(1.6%),P=.0007;深静脉血栓93例(2.5%)vs 122例(3.3%),P=.004,差异有统计学意义。

临床怎么用

  • 作者认为,临床需要时手术当日使用血管升压药可能是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare free flap outcomes between those who received and did not receive vasopressors (VPs) at the time of free flap reconstruction. STUDY DESIGN: This retrospective cohort study includes patients from January 2013 to January 2023. SETTING: This multicenter cohort study utilized data from the TriNetX Research Network which includes 80 health care organizations. METHODS: Head and neck cancer patients older than 18 years who underwent free flap reconstruction were separated into those who received or did not receive VPs on the day of surgery. The primary outcomes were flap failure defined by need for secondary free flap procedures, blood vessel repair, and other flap revision procedures. RESULTS: After propensity score matching, 7446 patients were analyzed. The VP group included 3723 patients (mean age [SD], 62.9 [11.4] years; 2511 males [67.4%]). The non-VP group included 3723 patients (mean age [SD], 63.0 [11.2] years; 2479 males [66.6%]). Free flap outcomes were not statistically different between groups (secondary free flap: 166 [4.5%] VP vs 155 [4.2%] non-VP, P = .04; vessel repair: 314 [8.4%] vs 319 [8.6%], P = .06; other flap revision procedures: 416 [11.2%] vs 449 [12.1%], P = .02). Bony flaps were found to have decreased rates of vessel repair in the VP group (47 [6.1%] vs 69 [9.0%], P = .003]. For secondary outcomes, pneumonia (173 [4.6%] vs 231 [6.2%], P = .0002), urinary tract infection (34 [1.0%] vs 59 [1.6%], P = .0007), and deep vein thrombosis (93 [2.5%] vs 122 [3.3%], P = .004) were significantly different. CONCLUSION: VP use is not significantly associated with free flap complications. These results imply that VP use on the same day as surgery may be safe if clinically necessary.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Le JP, Truong N, Newland M, et al. The Influence of Vasopressors on Free Flap Outcomes in Head and Neck Cancer Patients. Otolaryngol Head Neck Surg. 2024. PMID: 39101344. doi:10.1002/ohn.924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。